Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD
Dates
study started
completion around

Description

Summary

Official Title

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Details

Keywords

Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM, CAR T Cell, Solid Tumors, Autologous, T Cell, Mesothelin, MSLN, HLA-A2, Solid Tumors expressing MSLN, Pancreatic, Cell Therapy, Gene Therapy, blocker, PANC, OVCA, Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Malignant Mesothelioma, Pancreatic Neoplasms, xT CDx with HLA-LOH Assay

Eligibility

Locations

  • UCSD Moores Cancer Center accepting new patients
    La Jolla California 92093 United States
  • UCLA Medical Center accepting new patients
    Los Angeles California 90404 United States
  • Stanford University accepting new patients
    Stanford California 94305 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
A2 Biotherapeutics Inc.
Links
A2 Biotherapeutics Inc.
ID
NCT06051695
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 230 study participants
Last Updated